To view this email as a web page, click here.
 
NOTEWORTHY DRUG TRIALS
 
Popular insulin meets target in real-world study
Novo Nordisk's DEVOTE study reveals interesting findings.
Read more
 
Drug reduces migraine days in trials
An investigational treatment for the prevention of episodic and chronic migraine has met its primary end point in three phase 3 studies.
Read more
 
FDA approves Bayer's Bluetooth-enables auto-injector for multiple sclerosis
FDA has approved a supplemental Biologics License Application for Bayer's myBETAapp and BETACONNECT Navigator for multiple sclerosis patients.
Read more
 
SURVEY
 
State of the Industry Survey 2017
Take three minutes to answer our State of the Industry Survey. As a thank-you to survey-takers, when the survey closes, we will hold a drawing to give away not one, but two $200 Visa gift cards.
Take survey
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.